23 non-governmental

23andMe is a leading genetics and digital health company that leverages its vast database of genetic and phenotypic information to drive drug discovery and personalized healthcare. The company operates through two main segments: Consumer & Research Services, which provides direct-to-consumer genetic testing, and Therapeutics, which focuses on developing novel therapies based on genetic insights. By utilizing its proprietary research platform, 23andMe identifies therapeutic targets with strong genetic validation, particularly in oncology and immunology. Their pipeline includes programs such as 23ME-00610, an investigational antibody targeting CD200R1 for the treatment of solid tumors. The company aims to transform the drug development process by using human genetics to increase the probability of clinical success.